Sanofi Pharma Bristol-Myers Squibb SNC Withdraws Its Marketing Authorisation Application For DuoPlavin, Europe

Main Category: Cardiovascular / Cardiology
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 27 May 2008 - 9:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:3 stars

3 (2 votes)


The European Medicines Agency (EMEA) has been formally notified by Sanofi Pharma Bristol-Myers Squibb SNC of its decision to withdraw its application for a centralised marketing authorisation for the medicine DuoPlavin (fixed-dose combination tablets of 75 mg clopidogrel/75 mg acetylsalicylic acid and 75 mg clopidogrel/100 mg acetylsalicylic acid). DuoPlavin was expected to be used by patients already taking clopidogrel and acetylsalicylic acid for the approved indication of prevention of atherothrombotic events in acute coronary syndrome.

The application for marketing authorisation for DuoPlavin was submitted to the EMEA on 30 May 2007. At the time of the withdrawal, it was under review by the Agency's Committee for Medicinal Products for Human Use (CHMP).

In its official letter, the company stated that the withdrawal of DuoPlavin was based on the request of the CHMP regarding the need to document bioequivalence based on the current guideline on bioavailability and bioequivalence. The company informed in the letter that it intends to perform a new bioequivalence study measuring plasma levels of clopidogrel parent compound to address the CHMP's request but the results of that study will not be available in the timelines defined by the centralised procedure.

More information about DuoPlavin and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the EMEA website shortly.

Notes:

1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage.

http://www.emea.europa.eu

Article adapted by Medical News Today from original press release.
Visit our cardiovascular / cardiology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
EMEA. "Sanofi Pharma Bristol-Myers Squibb SNC Withdraws Its Marketing Authorisation Application For DuoPlavin, Europe." Medical News Today. MediLexicon, Intl., 27 May. 2008. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/108865.php>

APA
EMEA. (2008, May 27). "Sanofi Pharma Bristol-Myers Squibb SNC Withdraws Its Marketing Authorisation Application For DuoPlavin, Europe." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/108865.php.

Please note: If no author information is provided, the source is cited instead.




Cardiovascular / Cardiology

What Is Heart Rate?

A person's heart rate, also known as their pulse, refers to how many times their heart beats per minute. Our heart rates vary tremendously, depending on the demands we make on our bodies. Read more...

Most Popular Articles



Follow Our Cardiovascular News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cardiovascular / Cardiology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »